Skip to main content
TipRanks
Go Ultimate75% OFF

Eupraxia Pharmaceuticals (EPRX) Stock Statistics & Valuation Metrics

83 Followers

Total Valuation

Eupraxia Pharmaceuticals has a market cap or net worth of CAD 600.98M. The enterprise value is CAD 745.29M.

Market Cap
CAD 600.98M
Enterprise Value
CAD 745.29M

Share Statistics

Eupraxia Pharmaceuticals has 67,268,250 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
67,268,250
Owned by Insiders
10.01%
Owned by Institutions
32.35%

Financial Efficiency

Eupraxia Pharmaceuticals’s return on equity (ROE) is -0.48 and return on invested capital (ROIC) is -48.56%.

Return on Equity (ROE)
-0.48
Return on Assets (ROA)
-0.46
Return on Invested Capital (ROIC)
-48.56%
Return on Capital Employed (ROCE)
-0.49
Revenue Per Employee
0
Profits Per Employee
-801.05K
Employee Count
49
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Eupraxia Pharmaceuticals is -5.89. Eupraxia Pharmaceuticals’s PEG ratio is 0.42.

PE Ratio
-5.89
PS Ratio
0.00
PB Ratio
3.44
Price to FCF
-9.18
Price to Operating Cash Flow
-9.40
PEG Ratio
0.42

Income Statement

In the last 12 months, Eupraxia Pharmaceuticals had revenue of 0 and earned -39.25M in profits. Earnings per share was -1.05.

Revenue
0
Gross Profit
-241.88K
Operating Income
-39.11M
Pretax Income
-39.26M
Net Income
-39.25M
EBITDA
-38.86M
Earnings Per Share (EPS)
-1.05

Cash Flow

In the last 12 months, operating cash flow was -44.04M and capital expenditures -823,769, giving a free cash flow of -44.87M billion.

Operating Cash Flow
-44.04M
Free Cash Flow
-44.87M
Free Cash Flow per Share
-0.66

Dividends & Yields

Eupraxia Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-10.82%
Earnings Yield
-14.14%

Stock Price Statistics

Beta
1.16
52-Week Price Change
-1.56%
50-Day Moving Average
10.69
200-Day Moving Average
10.02
Relative Strength Index (RSI)
39.69
Average Volume (3m)
90.49K

Important Dates

Eupraxia Pharmaceuticals upcoming earnings date is Mar 30, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 09, 2026
Next Earnings Date
Mar 30, 2027
Ex-Dividend Date
―

Financial Position

Eupraxia Pharmaceuticals as a current ratio of 15.12, with Debt / Equity ratio of 0.19%

Current Ratio
15.12
Quick Ratio
15.12
Debt to Market Cap
0.00
Net Debt to EBITDA
2.07
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Eupraxia Pharmaceuticals has paid 19.42K in taxes.

Income Tax
19.42K
Effective Tax Rate
-0.00

Enterprise Valuation

Eupraxia Pharmaceuticals EV to EBITDA ratio is -5.23, with an EV/FCF ratio of -7.65.

EV to Sales
0.00
EV to EBITDA
-5.23
EV to Free Cash Flow
-7.65
EV to Operating Cash Flow
-7.79

Balance Sheet

Eupraxia Pharmaceuticals has CAD 125.61M in cash and marketable securities with CAD 3.40M in debt, giving a net cash position of CAD 122.21M billion.

Cash & Marketable Securities
CAD 125.61M
Total Debt
CAD 3.40M
Net Cash
CAD 122.21M
Net Cash Per Share
CAD 1.82
Tangible Book Value Per Share
CAD 1.78

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%

Analyst Forecast

The average price target for Eupraxia Pharmaceuticals is CAD 24.68, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
CAD 24.68
Price Target Upside
178.55% Upside
Analyst Consensus
Strong Buy
Analyst Count
9
Revenue Growth Forecast
―
EPS Growth Forecast
-17.60%

Scores

Smart Score
10
AI Score
44